Decision delayed over NH state Rx data

Share this article:
A federal judge took an unusual step last month of asking lawyers to critique a draft of his factual findings before ruling in IMS Health and Verispan’s high-profile challenge to New Hampshire’s state law limiting drug company access to doctors’ prescribing habits.

The Associated Press reported that Judge Paul Barbadoro asked lawyers for both sides in the case to meet with him to review his proposed factual findings, apparently in hopes to address some objections before ruling and providing the 1st US Circuit Court of Appeals in Boston with a clear decision.

Barbadoro cautioned that no one should try to predict his ruling from the draft, but some
of his comments showed his skepticism about key arguments—including the state’s contention that detailing drives up drug prices.

“If reasonable medical people disagree,” about the merits of various drugs for the same medical condition, “you have a stronger argument that speech restrictions are dangerous,” Barbadoro said. He expects to rule this month.  

Share this article:

Email Newsletters

More in News

Gilead reaps huge HCV sales, payer fury

Gilead reaps huge HCV sales, payer fury

Sovaldi's debut has been marked by plenty of criticism from payers and lawmakers, but the hep. C drug's launch, now confirmed to be the fastest of all time, has also ...

Bayer drug gets orphan label

Bayer drug gets orphan label

The FDA designation is for an experimental, inhaled form of ciprofloxacin intended to treat a rare lung condition.

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.